Search results
Results from the WOW.Com Content Network
Because synthetic cannabinoid molecular structures differ from THC and other illegal cannabinoids, synthetic cannabinoids were not technically illegal. Since the discovery of the use of synthetic cannabinoids for recreational use in 2008, some synthetic cannabinoids have been made illegal , but new analogs are continually synthesized to avoid ...
JWH-018 is a full agonist of both the CB 1 and CB 2 cannabinoid receptors, with a reported binding affinity of 9.00 ± 5.00 nM at CB 1 and 2.94 ± 2.65 nM at CB 2. [6] JWH-018 has an EC 50 of 102 nM for human CB 1 receptors, and 133 nM for human CB 2 receptors. [16]
Significant experience in brodifacoum poisonings has been gained in many human cases where it has been used in attempted suicides, necessitating long periods of vitamin K treatment. In March 2018, cases of severe coagulopathy and bleeding associated with synthetic cannabinoid use contaminated with brodifacoum were reported in five states of the US.
In 2021, MDMB-4en-PINACA was the most common synthetic cannabinoid identified by the Drug Enforcement Administration in the United States. [10] MDMB-4en-PINACA differs from 5F-MDMB-PINACA due to replacement of 5-fluoropentyl with a pent-4-ene moiety (4-en).
O-1602 is a synthetic compound most closely related to abnormal cannabidiol, and more distantly related in structure to cannabinoid drugs such as THC.O-1602 does not bind to the classical cannabinoid receptors CB 1 or CB 2 with any significant affinity, but instead is an agonist at several other receptors which appear to be related to the cannabinoid receptors, particularly GPR18 and GPR55.
MDMB-BINACA (MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. It has a similar chemical structure to potent cannabinoid agonists previously reported such as ADB-BUTINACA and MDMB-5'Br-BUTINACA, and is believed to have similar ...
JWH-015 is a chemical from the naphthoylindole family that acts as a subtype-selective cannabinoid agonist.Its affinity for CB 2 receptors is 13.8 nM, while its affinity for CB 1 is 383 nM, meaning that it binds almost 28 times more strongly to CB 2 than to CB 1. [1]
Dexanabinol (HU-211 or ETS2101 [1]) is a synthetic cannabinoid derivative in development by e-Therapeutics plc. It is the "unnatural" enantiomer of the potent cannabinoid agonist HU-210 . [ 2 ] Unlike other cannabinoid derivatives, HU-211 does not act as a cannabinoid receptor agonist, but instead as an NMDA antagonist . [ 3 ]